Lipids, thrombosis and cardiovascular disease in diabetes

Proceedings of the Nutrition Society

Volumn 56, Issue 1999, 1997, Pages 273-280

  Yudkin, John S ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL;

BLOOD; CARDIOVASCULAR DISEASE; HUMAN; HYPERLIPIDEMIA; LIPID METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; RISK FACTOR; THROMBOSIS;

CARDIOVASCULAR DISEASES; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERLIPIDEMIAS; LIPID METABOLISM; RISK FACTORS; THROMBOSIS;

EID: 0031086702     PISSN: 00296651     EISSN: None     Source Type: Journal    
DOI: 10.1079/pns19970031     Document Type: Article

References (45)

1. Ader, M. & Bergman, R. N. (1994). Importance of transcapillary insulin transport to dynamics of insulin action after intravenous glucose. American Journal of Physiology 266, E17-E25.
2. Anfossa, F., Chomiki, N., Alessi, M. C., Vague, P. & Juhan-Vague, I. (1993). Plasminogen activator inhibitor-1 synthesis in the human hepatoma cell line Hep G2: metformin inhibits the stimulating effect of insulin. Journal of Clinical Investigation 91, 2185-2193.
3. Asplund-Carlson, A., Hamsten, A., Wiman, B. & Carlson, L. A. (1993). Relationship between plasma plasminogen activator inhibitor-1 activity and VLDL triglyceride concentration, insulin levels and insulin sensitivity: studies in randomly selected normo- and hypertriglyceridaemic men. Diabetologia 36, 817-825.
4. Austin, M. A. (1989). Plasma triglyceride as a risk factor for coronary heart disease. The epidemiologic evidence and beyond. American Journal of Epidemiology 129, 249-259.
5. Austin, M. A., King, M.-C., Vranizan, K. M. & Krauss, R. M. (1990). Atherogenic lipoprotein phenotype: a proposed genetic marker for coronary heart disease risk. Circulation 82, 495-506.
6. Austin, M. A., Mykkänen, L., Kuusisto, J., Edwards, K. L., Nelson, C., Haffner, S. M., Pyörälä, K. & Laakso, M. (1995). Prospective study of small LDLs as a risk factor for non-insulin dependent diabetes mellitus in elderly men and women. Circulation 92, 1770-1778.
7. Bradford Hill, A. (1965). The environment and disease: Association or causation? Proceedings of the Royal Society of Medicine 58, 295-300.
8. Casscells, W., Hathor, B., David, M., Krabach, T., Vaughn, W. K., McAllister, H. A., Bearman, G. & Willerson, J. T. (1996). Thermal detection of cellular infiltrates in living atherosclerotic plaques: possible implications for plaque rupture and thrombosis. Lancet 347, 1447-1449.
9. Chait, A., Brazg, R. L., Tribble, D. L. & Krauss, R. L. (1993). Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. American Journal of Medicine 94, 351-356.
10. Eckel, R. H. (1989). Lipoprotein lipase: a multifunctional enzyme relevant to common metabolic diseases. New England Journal of Medicine 320, 1060-1068.
11. Feingold, K. R., Grunfeld, C., Pang, M., Doerrler, W. & Krauss, R. M. (1992). LDL subclass phenotypes and triglyceride metabolism in non-insulin-dependent diabetes. Arteriosclerosis and Thrombosis 12, 1496-1502.
12. Folsom, A. R., Qamhieh, H. T., Wing, R. R., Jeffery, R. W., Stinson, V. L., Kuller, L. H. & Wu, K. K. (1993). Impact of weight loss on plasminogen activator inhibitor (PAI-1), factor VII, and other hemostatic factors in moderately overweight adults. Arteriosclerosis and Thrombosis 13, 162-169.
13. Fontbonne, A., Eschwège, E., Cambien, F., Richard, J.-L., Ducimetière, P., Thibult, N., Warnet, J.-M., Claude, J.-R. & Rosselin, G.-E. (1989). Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes. Diabetologia 32, 300-304.
14. Fuller, J. H., Shipley, M. J., Rose, G., Jarrett, R. J. & Keen, H. (1980). Coronary-heart-disease risk and impaired glucose tolerance. The Whitehall Study. Lancet i, 1373-1376.
15. Gray, R. P., Patterson, D. L. H. & Yudkin, J. S. (1993a). Plasminogen activator inhibitor activity in diabetic and nondiabetic survivors of myocardial infarction. Arteriosclerosis and Thrombosis 13, 415-420.
16. Gray, R. P., Yudkin, J. S. & Patterson, D. L. (1993b). Enzymatic evidence of impaired reperfusion in diabetic patients after thrombolytic therapy for acute myocardial infarction: A role for plasminogen activator inhibitor? British Heart Journal 70, 530-536.
17. Gray, R. P., Yudkin, J. S. & Patterson, D. L. H. (1993c). Plasminogen activator inhibitor: a risk factor for myocardial infarction in diabetic subjects. British Heart Journal 69, 228-232.
18. Haffner, S. M., Stern, M. P., Hazuda, H. P., Mitchell, B. D. & Patterson, J. K. (1990). Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? Journal of the American Medical Association 263, 2893-2898.
19. Hamsten, A., de Faire, U., Walldius, G., Dahlen, G., Szamosi, A., Landou, C., Blomback, M. & Wiman, B. (1987). Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet ii, 3-9.
20. Juhan-Vague, I., Thompson, S. G. & Jespersen, J. (1993). Involvement of the hemostatic system in the insulin resistance syndrome: a study of 1500 patients with angina pectoris. Arteriosclerosis and Thrombosis 13, 1865-1873.
21. King, G. L. & Johnson, S. M. (1985). Receptor-mediated transport of insulin across endothelial cells. Science 227, 1583-1586.
22. Laakso, M., Edleman, S. V.. Brechtel, G. & Baron, A. D. (1992). Impaired insulin-mediated skeletal muscle blood flow in patients with NIDDM. Diabetes 41, 1076-1083.
23. Laakso, M., Lehto, S., Penttilä, I. & Pyörälä, K. (1993). Lipids and lipoproteins predicting coronary heart disease mortality and morbidity in patients with non-insulin-dependent diabetes. Circulation 88, 1421-1430.
24. Lahdenperä, S., Sane, T., Vuorinen-Markkola, H., Knudsen, P. & Taskinen, M. R. (1995). LDL particle size in mildly hypertriglyceridemic subjects: no relation to insulin resistance or diabetes. Atherosclerosis 113, 227-236.
25. Latron, Y., Chautan, M., Anfosso, F., Alessi, M. C., Nalbone, G., Lafont, H. & Juhan-Vague, I. (1991). Stimulating effect of oxidised low density lipoprotein on plasminogen activator inhibitor-1 synthesis by endothelial cells. Arteriosclerosis and Thrombosis 11, 1821-1829.
26. Law, M. R., Wald, N. J. & Thompson, S. G. (1994). By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? British Medical Journal 308, 367-372.
27. Mendall, M. A., Patel, P., Ballam, L., Strachan, D. & Northfield, T. C. (1996). C reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study. British Medical Journal 312, 1061-1065.
28. Miller, G. J., Martin, J. C., Webster. J., Wilkes, H., Miller, N. E., Wilkinson, W. H. & Meade, T.W. (1986). Association between dietary fat intake and plasma factor VII coagulant activity - a predictor of cardiovascular mortality. Atherosclerosis 60, 269-277.
29. Nagi, D. K., Hendra, T. J., Ryle, A. J., Cooper, T. M., Temple, R. C., Clark, P. M. S., Schneider, A. E., Hales, C. N. & Yudkin, J. S. (1990). The relationship of concentrations of insulin, intact proinsulin and 32-33 split proinsulin with cardiovascular risk factors in type 2 (non-insulin dependent) diabetic subjects. Diabetologia 33, 532-537.
30. Panahloo, A., Mohamed-Ali, V., Lane, A., Green, F., Humphries, S. E. & Yudkin, J. S. (1995). Determinants of plasminogen activator inhibitor-1 activity in treated NIDDM and its relation to a polymorphism in the plasminogen activator inhibitor-1 gene. Diabetes 44, 37-42.
31. Panahloo, A. & Yudkin, J. S. (1996). Diminished fibrinolysis in diabetes mellitus and its implication for diabetic vascular disease. Coronary Artery Disease 7, 723-731.
32. Potter van Loon, B. J., Kluft, C., Radder, J. K., Blankenstein, M. A. & Meinders, A. E. (1993). The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance. Metabolism 42, 945-949.
33. Pyörälä, K., Pedersen, T. R. & Kjekshus, J. (1995). The effect of cholesterol lowering with simvastatin on coronary events in diabetic patients with coronary heart disease. Diabetes 44, Suppl. 1, 35A Abstr.
34. Rosengren, A., Welin, L., Tsipogianni, A. & Wilhelmsen, L. (1989). Impact of cardiovascular risk factors on coronary heart disease and mortality among middle aged diabetic men: a general population study. British Medical Journal 299, 1127-1131.
35. Sawdey, M. S. & Loskutoff, D. J. (1991). Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Journal of Clinical Investigation 88, 1346-1353.
36. Scandinavian Simvastatin Survival Study Group (1994). Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344, 1383-1389.
37. Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H. & Packard, C. J. (1995). Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. New England Journal of Medicine 333, 1301-1307.
38. Stamler, J., Vaccaro, O., Neaton, J. D. & Wentworth, D. for the Multiple Risk Factor Intervention Trial Research Group (1993). Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16, 434-444.
39. Steinberg, D., Parthasarathy, S., Carew, T. E., Khoo, J. C. & Witztum, J. L. (1989). Modifications of low density lipoprotein that increase its atherogenicity. New England Journal of Medicine 320, 915-924.
40. Stewart, M. W., Laker, M. F., Dyer, R. G., Game, F., Mitcheson, J., Winocour, P. H. & Alberti, K. G. M. M. (1993). Lipoprotein compositional abnormalities and insulin resistance in type II diabetic patients with mild hyperlipidemia. Arteriosclerosis and Thrombosis 13, 1046-1052.
41. Stiko-Rahm, A., Wiman, B., Hamsten, A. & Nilsson, J. (1990). Secretion of plasminogen activator inhibitor-1 from cultured human umbilical vein cells is induced by very low density lipoprotein. Arteriosclerosis 10, 1067-1073.
42. Tan, K. C. B., Cooper, M. B., Ling, K. L. E., Griffin, B. A., Freeman, D. J., Packard, C. J., Shepherd, J., Hales, C. N. & Betteridge, D. J. (1995). Fasting and postprandial determinants for the occurrence of small dense LDL species in non-insulin-dependent diabetic patients with and without hypertriglyceridaemia: the involvement of insulin, insulin precursor species and insulin resistance. Atherosclerosis 113, 273-287.
43. Uusitupa, M. I. J., Niskanen, L. K., Siitonen, O., Voutilainen, E. & Pyörälä, K. (1990). 5-year incidence of atherosclerotic vascular disease in relation to general risk factors, insulin level, and abnormalities in lipoprotein composition in non-insulin-dependent diabetic and nondiabetic subjects. Circulation 82, 27-36.
44. Vague, Ph., Juhan-Vague, I., Aillaud, M. F., Badier, C., Viard, R., Alessi, M. C. & Collen, D. (1986). Correlations between blood fibrinolytic activity, plasminogen activator inhibitor levels, plasma insulin and relative body weight in normal and obese subjects. Metabolism 35, 250-253.
45. Yudkin, J. S. (1993). How can we best prolong life? The benefits of coronary risk factor reduction in non-diabetic and diabetic subjects. British Medical Journal 306, 1313-1318.